Hansa Biopharma AB chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 3.13
Dividend & YieldN/A£ (N/A)
Beta 1.02
Market capitalization N/A
Operating cash flow -508.89M
ESG Scores unknown

Company description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Sector: - Industry:

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 36.65M 10.15M -23.9M 28.58M
Total Cashflows From Investing Activities -387.48M 85.78M 182.53M -2.4M
Net Borrowings -44k -4.42M -4.67M -4.86M
Total Cash From Financing Activities 450.31M -8.88M 1.07B -4.86M
Change To Operating Activities -8.4M 1.06M 102.81M -16.09M
Issuance Of Stock 457.55M 877k 1.11B
Net Income -247.97M -360.01M -420.85M -548.28M
Change In Cash -141.64M -257.74M 957.66M -488.02M
Effect Of Exchange Rate 93k 131k -501k 403k
Total Cash From Operating Activities -204.56M -334.77M -290.27M -481.17M
Depreciation 1.25M 6.91M 7.67M 6.51M
Change To Account Receivables 450k -464k 412k -9.6M
Other Cashflows From Financing Activities -7.2M -5.34M -41.26M
Change To Netincome 12.91M 7.58M 43.59M 55.62M
Capital Expenditures -2.37M -2.7M -294k -2.4M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 154.56M 192.95M 227.19M 230.76M
Income Before Tax -248.01M -359.59M -420.89M -548.13M
Net Income -247.97M -360.01M -420.85M -548.28M
Selling General Administrative 90.39M 167.31M 202.99M 327.27M
Gross Profit 2.44M 2.5M 5.1M 18.45M
Ebit -241.78M -357.6M -425.08M -539.58M
Operating Income -241.78M -357.6M -425.08M -539.58M
Interest Expense -706k -466k -257k -694k
Income Tax Expense -40k 417k -40k 152k
Total Revenue 3.36M 3.36M 6.1M 33.88M
Cost Of Revenue 916k 866k 997k 15.43M
Total Other Income ExpenseNet -6.24M -2M 4.18M -8.55M
Net Income From Continuing Ops -247.97M -360.01M -420.85M -548.28M
Net Income Applicable To Common Shares -247.97M -360.01M -420.85M -548.28M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 84.94M 101.42M 192.37M 255.24M
Total Stockholder Equity 859.88M 562.82M 1.24B 757.57M
Other Current Liabilities 14.84M 7.65M 30.76M 32.94M
Total Assets 944.82M 664.24M 1.43B 1.01B
Common Stock 40.68M 41.45M 45.9M 46.34M
Other Current Assets 149k 6.74M 6.43M 26.56M
Retained Earnings -611.81M -971.82M -1.31B -1.86B
Treasury Stock 30.49M 79.74M -1.56M -1.73M
Cash 439.44M 181.7M 1.14B 651.34M
Total Current Liabilities 72.33M 94.54M 114.2M 171.22M
Other Stockholder Equity 31.22M 81.16M -137k 128k
Property, Plant, and Equipment 5.88M 15.14M 9.7M 41.7M
Total Current Assets 866.22M 615.74M 1.39B 942.34M
Net Tangible Assets 826.68M 529.47M 1.21B 728.81M
Net Receivables 7.41M 5.26M 7.7M 23.24M
Accounts Payable 40.43M 50.57M 26.67M 53.36M


Insider Transactions

Here are the insider transactions of stock shares related to Hansa Biopharma AB:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Hansa Biopharma AB. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Hansa Biopharma AB

Here is the result of two systematic investment strategies applied to Hansa Biopharma AB. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Hansa Biopharma AB

The following chart shows the equity curve of the two systematic investment strategies applied to Hansa Biopharma AB:

Hansa Biopharma AB automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 0% on the backtest period.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

0.0 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Hansa Biopharma AB

This is the result of two momentum investment strategies applied to Hansa Biopharma AB. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Hansa Biopharma AB

The following chart shows all the entries opened by the momentum investment system on Hansa Biopharma AB:

Hansa Biopharma AB momentum entries
  • The first momentum investment strategy would give 0.0% of return on Hansa Biopharma AB. That represents 0.0£ of latent gain with 277.3£ of employed capital.
  • The second momentum investment strategy would give 0% of return on Hansa Biopharma AB. That represents 0.0£ of latent gain with 0.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

0.0 %

Latent gain

0.0 £

Invested capital

277.3 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Momentum equity curve on Hansa Biopharma AB

The following chart shows the equity curve of the two momentum strategies applied to Hansa Biopharma AB:

Hansa Biopharma AB momentum equity

Note: the dividends potentially given by Hansa Biopharma AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Hansa Biopharma AB

The following chart shows the employed capital evolution of the two momentum strategies on Hansa Biopharma AB since the beginning:

Hansa Biopharma AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on Hansa Biopharma AB

Buy the dip entry openings on Hansa Biopharma AB

Hansa Biopharma AB

The performance achieved by the robo-advisor on Hansa Biopharma AB is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows Hansa Biopharma AB stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Hansa Biopharma AB, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to Hansa Biopharma AB

The following chart shows the result of the investment strategy applied to Hansa Biopharma AB:

Hansa Biopharma AB

Note: the dividends potentially given by Hansa Biopharma AB are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Hansa Biopharma AB

The following chart shows the employed capital evolution since the beginning of the investment strategy on Hansa Biopharma AB:

Hansa Biopharma AB

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Hansa Biopharma AB

In this section, I will compare the three previous investment strategies applied to Hansa Biopharma AB.

Equity curve comparison on Hansa Biopharma AB

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Hansa Biopharma AB investment strategy comparison

Employed capital comparison on Hansa Biopharma AB

Hansa Biopharma AB investment comparison

Performance comparison on Hansa Biopharma AB

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 0% 0.0£ 0.0£ 0.0%
Momentum 1 quarter 0.0% 0.0£ 277.3£ 0.0%
Momentum 2 quarters 0% 0.0£ 0.0£ -0.0%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

0.0 %

Momentum 1Q

-0.0 %

Momentum 2Q

-0.0 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Hansa Biopharma AB:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Hansa Biopharma AB and the other stocks. There may be false positives or some missing correlated stocks. If the price of Hansa Biopharma AB does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Hansa Biopharma AB
Country Sweden
City Lund
Address PO Box 785
Phone 46 46 16 56 70
Website www.hansabiopharma.com
FullTime employees 145
Industry
Sector
Exchange XLON
Ticker 0RC7.XLON
Market www.londonstockexchange.com

Hansa Biopharma AB ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown